UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033730
Receipt number R000038463
Scientific Title Monitoring inner ear hydrops by using Gd-MRI
Date of disclosure of the study information 2018/08/16
Last modified on 2022/04/19 09:41:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Monitoring inner ear hydrops by using Gd-MRI

Acronym

Gd-MR for hydrops patients

Scientific Title

Monitoring inner ear hydrops by using Gd-MRI

Scientific Title:Acronym

Gd-MR for hydrops patients

Region

Japan


Condition

Condition

inner ear disorders

Classification by specialty

Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

There are two compartments separated by the epithelial structure in the inner ear: perilymph and endolymph. Endolymphatic hydrops is a state in which the proportion of the latter is increased, and it is known as a pathology of variable symptoms of inner ear disorder (hearing loss, dizziness, equilibrium disorder). Recently, a technique to visualize endolymph in the contrast MRI has been reported: IV injection of the contrast agent 4 hours before MRI imaging renders endolymph with nice spatial resolution. Diagnostic criteria in Japan for Meniere's disease, which is a clinical disease name of endolymphatic hydrops, also includes this imaging tests.
The main purpose of this study is to analyze the changes on the contrast MRI before, during and after the time of treatments in endolymphatic hydrops patients. The secondary purpose is to optimize image analysis of the method at our 3T contrast MRI (GE).

Basic objectives2

Others

Basic objectives -Others

Regarding this research method, there is little report on the image analysis with MR scan of GE. Diagnostic power using the machine is also examined exploratively in this research.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Comparison of visualization of endolymphatic edema before, during and after treatments.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Among clinical endolymphatic hydrops patients who are visiting Keio University Hospital, have the capacity to agree and with whom treatments for hydrops will be given.

Key exclusion criteria

1) patients with kidney dysfunction
2) patients with a history of allergy by Gd contrast agent

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Sho
Middle name
Last name Kanzaki

Organization

Keio University Hospital

Division name

Otorhinolaryngology

Zip code

160-8582

Address

35, Shinanomachi Shinjuku Tokyo Japan

TEL

03-5363-3827

Email

skan@keio.jp


Public contact

Name of contact person

1st name Sho
Middle name
Last name Kanzaki

Organization

Keio University Hospital

Division name

Otorhinolaryngology

Zip code

160-8582

Address

35, Shinanomachi Shinjuku Tokyo Japan

TEL

03-5363-3827

Homepage URL


Email

otol.group@gmail.com


Sponsor or person

Institute

Keio University Hospital

Institute

Department

Personal name



Funding Source

Organization

AMED, JSPS, MHLW, Donations

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethics Committee

Address

35 Shinanomachi, Shinjuku, Tokyo

Tel

03-3353-1211

Email

med-rinri-jimu@adst.keio.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 08 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 05 Month 11 Day

Date of IRB

2018 Year 07 Month 02 Day

Anticipated trial start date

2018 Year 08 Month 15 Day

Last follow-up date

2022 Year 03 Month 30 Day

Date of closure to data entry

2022 Year 03 Month 30 Day

Date trial data considered complete

2022 Year 03 Month 30 Day

Date analysis concluded

2022 Year 03 Month 30 Day


Other

Other related information

Changes in the MR images will be evaluated


Management information

Registered date

2018 Year 08 Month 13 Day

Last modified on

2022 Year 04 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038463


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name